Pharmaron Beijing Co., Ltd. (3759.HK)

HKD 14.46

(7.11%)

EBITDA Summary of Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd.'s latest annual EBITDA in 2023 was 2.94 Billion CNY , up 15.36% from previous year.
Pharmaron Beijing Co., Ltd.'s latest quarterly EBITDA in 2024 Q2 was 1.04 Billion CNY , up 117.72% from previous quarter.
Pharmaron Beijing Co., Ltd. reported an annual EBITDA of 2.52 Billion CNY in 2022, up 0.66% from previous year.
Pharmaron Beijing Co., Ltd. reported an annual EBITDA of 2.49 Billion CNY in 2021, up 59.37% from previous year.
Pharmaron Beijing Co., Ltd. reported a quarterly EBITDA of 366.77 Million CNY for 2024 Q1, down -27.57% from previous quarter.
Pharmaron Beijing Co., Ltd. reported a quarterly EBITDA of 450.19 Million CNY for 2024 Q3, down -56.12% from previous quarter.

Annual EBITDA Chart of Pharmaron Beijing Co., Ltd. (2023 - 2014)

Historical Annual EBITDA of Pharmaron Beijing Co., Ltd. (2023 - 2014)

Year	EBITDA	EBITDA Growth
2023	2.94 Billion CNY	15.36%
2022	2.52 Billion CNY	0.66%
2021	2.49 Billion CNY	59.37%
2020	1.71 Billion CNY	59.05%
2019	1.03 Billion CNY	46.26%
2018	700.55 Million CNY	43.87%
2017	486.93 Million CNY	50.42%
2016	324.86 Million CNY	86.86%
2015	168.26 Million CNY	76.78%
2014	92.73 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	1.04 Billion CNY	117.72%
2024 Q1	366.77 Million CNY	-27.57%
2024 Q3	450.19 Million CNY	-56.12%
2023 Q1	449.07 Million CNY	-30.94%
2023 FY	- CNY	15.36%
2023 Q4	650.6 Million CNY	54.51%
2023 Q3	421.08 Million CNY	-25.87%
2023 Q2	568.04 Million CNY	26.49%
2022 Q1	311.63 Million CNY	-61.35%
2022 FY	- CNY	0.66%
2022 Q4	650.22 Million CNY	60.84%
2022 Q3	404.26 Million CNY	-26.78%
2022 Q2	552.08 Million CNY	77.16%
2021 FY	- CNY	59.37%
2021 Q4	806.24 Million CNY	52.08%
2021 Q3	530.15 Million CNY	23.48%
2021 Q1	333.62 Million CNY	-29.74%
2021 Q2	429.33 Million CNY	28.69%
2020 Q2	396.97 Million CNY	152.63%
2020 Q1	157.13 Million CNY	-40.0%
2020 Q3	312.29 Million CNY	-21.33%
2020 FY	- CNY	59.05%
2020 Q4	474.81 Million CNY	52.04%
2019 Q1	84.89 Million CNY	-60.48%
2019 FY	- CNY	46.26%
2019 Q4	261.88 Million CNY	21.72%
2019 Q3	215.15 Million CNY	50.53%
2019 Q2	142.93 Million CNY	68.36%
2018 Q1	64.52 Million CNY	-59.71%
2018 FY	- CNY	43.87%
2018 Q4	214.8 Million CNY	4.11%
2018 Q3	206.33 Million CNY	75.02%
2018 Q2	117.88 Million CNY	82.71%
2017 Q4	160.15 Million CNY	0.0%
2017 FY	- CNY	50.42%
2016 FY	- CNY	86.86%
2015 FY	- CNY	76.78%
2014 FY	- CNY	0.0%

Peer EBITDA Comparison of Pharmaron Beijing Co., Ltd.

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	-3130.429%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	-505.438%